[Methodological recommendations for surgical care in patients with hemophilia A receiving prophylactic therapy with emicizumab].

Methodological recommendations for surgical care in patients with hemophilia A receiving prophylactic therapy with emicizumab. Recommendations of the expert group. Moscow, 2024.

[Surgery in patients with severe or inhibitory hemophilia A under prevention injection of emicizumab].

Objective: To determine the features of preoperative hemostatic therapy and laboratory control in patients with severe and inhibitory forms of hemophilia A under preventive treatment by FVIII.

Material And Methods: Four patients with severe and inhibitory forms of hemophilia A underwent surgery between 2021 and 2022. All patients received Emicizumab (the first monoclonal drug for «non-factor» therapy of hemophilia) for prevention of specific hemorrhagic signs of hemophilia.

[Acute arterial thrombosis in hemophilia with inhibitory antibodies].

The authors demonstrate an importance of personalized approach to perioperative hemostatic therapy in a 48-year-old patient with hemophilia A and inhibitory antibodies. Laparoscopic hernia repair and extraction of 15 decayed teeth were performed. Hemostatic therapy included AICC and rFVIIa.

[Inhibitory and mild forms of hemophilia: diagnostic difficulties, surgical complications].

Aim: To identify patients with hemophilia who have a high risk of postoperative hemorrhagic complications.

Material And Methods: Prospective trial included 69 patients aged 18-71 years (median 29) with congenital hemophilia A and B. They underwent elective and emergency treatment for abdominal and thoracic pathology at the National Medical Research Center for Hematology in 2011-2016.